MISSISSAUGA, ON, Feb. 4, 2025 /CNW/ -- 'One cupcake won't kill you', 'I'm going to get diabetes just looking at that', 'That person doesn't look like they have diabetes.' New survey results and a short film, Above the Bias, released today by Abbott (NYSE: ABT) highlight how everyday comments like these may affect people living with diabetes.
People living with diabetes – which now includes 4 million diagnosed in Canada2 – face many barriers to receiving care. Survey data reveal that the misconceptions and stereotypes around the condition can weigh heavily on the minds of those living with diabetes, creating one more barrier and potentially preventing them from managing their health.
Data from a survey of more than 2,600 people living with diabetes across eight countries, including Canada, highlights they may not be getting the care they need due to the shame and stigma around their condition, which can lead to real and often unnoticed health consequences: 1
But while words can hurt, they can also help.
Above the Bias
Abbott's new Above the Bias initiative aims to help others see the world from the perspective of someone living with diabetes. The initiative builds upon efforts by several diabetes organizations, patient advocacy groups, and experts that continue to work to reduce stigma about diabetes3. People can learn more about Above the Bias and watch the film at AboveBias.com.
"From the very early days of Libre, it's been our job to make living with diabetes easier," said Chris Scoggins, executive vice president of Abbott's diabetes care business. "But technology alone can't fix every barrier that people face. We're committed to doing our part, but we can't do it alone. We need the ongoing help of others to support people living with diabetes, so they can get the care they need to manage their health."
About FreeStyle Libre systems4:
Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading5 FreeStyle Libre (Libre) sensor-based glucose monitoring portfolio, which today is used by about 7 million people in more than 60 countries. People use Libre to see their glucose levels in real-time, making it easier to act, such as taking insulin or adjusting food and activity, to make progress on their health goals.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at Abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
ADC-106522 v1.0
SOURCE Abbott